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REL, a member of the NF-κB family of transcription factors, is a 
newly defined risk locus for rheumatoid arthritis
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A genome-wide association study of rheumatoid arthritis in 2418 cases and 4504 controls 
from North America identified an association at the REL locus, encoding c-Rel, on 
chromosome 2p13 (rs13031237, p=6.01 × 10-10). Replication in independent case-control 
datasets comprising 2604 cases and 2882 controls confirmed this association, yielding an 
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allelic OR=1.25 (95%CI 1.177-1.318, p = 3.08 × 10-14) for marker rs13031237 and an 
allelic OR= 1.21 (95%CI 1.150-1.282, p = 2.60 × 10-11) for marker rs13017599 in the 
combined dataset. The combined dataset also provides definitive support for associations at 
both CTLA4 (rs231735; OR=0.85, 95% CI 0.81-0.90; p= 6.25 × 10-9) and BLK (rs2736340; 
OR= 1.19, 95% CI 1.125-1.268; p=5.69 × 10-9 ). C-Rel is an NF-kappaB family member 
with distinct functional properties in hematopoietic cells, and its association with RA 
suggests disease pathways that involve other recently identified RA susceptibility genes 
including CD40, TRAF1, TNFAIP3, and PRKCQ1,2.
Rheumatoid arthritis [RA (MIM 180300)] is a common autoimmune disorder affecting 
approximately 1% of populations of European origin and whose predominant manifestation 
is inflammation with bone and cartilage destruction in diarthrodial joints. The genetic basis 
for RA is complex, with at least six genes generally accepted as associated with disease in 
populations of European origin, including HLA-DRB1, PTPN22, STAT4, TRAF1, and 
TNFAIP31. A number of additional loci have recently been reported as a result of expanded 
genome-wide association studies3 and metanalyses2. Many of these are likely to reflect true 
associations, although a convincing demonstration often requires very large samples sizes, 
given that many of the associations at these loci are quite modest. In most cases the 
causative allele(s) have not been identified, and therefore the actual contribution to disease 
risk at these loci is unknown.
The diagnosis of rheumatoid arthritis is based on clinical criteria established over two 
decades ago4. However, these criteria do not yet include antibody reactivity to cyclic 
citrullinated peptides (CCP), the presence of which is a highly sensitive and specific marker 
for the diagnosis of RA; between 50 and 80% of patients meeting standard criteria for RA 
exhibit anti-CCP antibodies5. Remarkably, the classical HLA-DRB1 associations with RA 
are entirely restricted to this phenotypic subgroup6, as are many of the other reported 
genetic associations. In addition to this phenotypic heterogeneity, there is evidence for 
genetic heterogeneity in risk for RA among different racial groups7, and this has 
complicated efforts at replication. Given these considerations, it is apparent that additional 
risk genes for RA remain to be discovered. For these reasons we undertook an expansion of 
our previous genome-wide association study of rheumatoid arthritis8, restricted to North 
American cases of European origin that were overwhelmingly (~95%) anti-CCP antibody 
positive. We also assembled a large case-control population for replication studies.
All new genotyping of case samples for this study was performed on Illumina HapMap370 
BeadArray typing platforms, and after quality control filtering (see Supplementary 
Methods), a combined dataset of 2418 RA cases and 4504 controls was available for WGA 
analysis that had been genotyped on 278502 SNPs that passed all quality control filters 
applied to each set of data. The cases are derived in part from affected sibling pair families 
of the North American Rheumatoid Arthritis Consortium (NARAC) previously reported8 
(one case per family), as well as new collections from both the U.S. and Canada (see 
Supplementary Table 1A). The genome-wide lambda value inflation of chi-square values 
was calculated to be 1.21, allowing for the large sample size. Structured association was 
therefore applied to correct for population stratification by matching homogeneous clusters 
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of cases and controls, as implemented in PLINK. The genome-wide lambda value after 
adjustment was calculated to be 1.06.
Figure 1 displays a graphical summary of the results of the genome-wide analysis as 
implemented in PLINK, after conditioning on clusters. As noted in previous studies, the 
largest association signal is in an extended region within the MHC achieving a maximal 
level significance of p=9.50 × 10-104 in this study. (The y axis is truncated at - log p=27 in 
Figure 1). In addition, the previously reported associations8 are confirmed at PTPN22 
(rs2476601, p= 1.62 × 10-21) and the TRAF1/C5 regions (maximal association at rs881375, 
p= 4.09×10-8). However, after PTPN22 the second most significant association is observed 
on chromosome 2 in the region of REL, where two markers provide highly significant 
evidence of association (rs13031237, allele specific p=6.01 × 10-10 and rs13017599, allele 
specific p=9.05 × 10-9), as shown in Table 1. This is a novel finding, since REL has not been 
brought forward as a candidate region for RA risk by any of the previous association studies 
in RA, although a recent publication has reported an association with Coeliac disease9. At 
lower levels of significance, we also noted evidence of association (Table 1) with CTLA4 (rs 
6748358, p= 8.24 × 10-5) and a SNP marker in the region of the BLK locus (rs2736340, p= 
6.06 × 10-7). A complete list of results at significance level p<0.01 for the entire dataset is 
provided (Supplementary Table 2).
In order to establish that these results are robust to various analytic approaches, we also 
performed analysis using Eigenstrat. Before performing the PCA, we removed markers in 
the region of chromosome 8p that shows inversions in Northern Europeans (8.135-11.936 
Mb) and markers in the centromeric region of chromosome 17q21.31 (40-43 Mb) that is 
polymorphic in European origin populations10. We also removed markers around the HLA 
region that are related to European ancestry and also rheumatoid arthritis risk (from 24-36 
Mb). These HLA-related markers were also removed for analyses that estimate inflation of 
the genome-wide inflation of test statistics that can arise from differences in population 
ancestry, since the HLA region includes many hundreds of markers that are associated with 
RA risk6. The association tests with all markers (including those on chromosomes 6p, 8p, 
and 17p) were performed adjusting for the eigenvectors derived using Eigenstrat to remove 
population admixture effects. The lambda value was 1.20 prior to PCA correction and this 
value reduced to a lambda value of 1.06 after PCA correction. Results from Eigenstrat 
analysis along with trend tests from PLINK are presented in supplementary table 3. Despite 
some genome-wide excess in the expected number of positive results from tests for 
association, the specific findings for REL did not appear to be influenced substantially by 
population structure. As shown in supplementary table 3, we found that without and with 
adjustment for population structure the p-values and odds ratios associating the SNPs we 
queried were quite similar. For example, for rs13031237, the odds ratio and p-value without 
adjustment for population structure in the combined genome-wide association analysis was 
1.278 (p=5.2 × 10-11) versus an odds ratio of 1.268 with adjustment (p=6.0 × 10-10).
In order to confirm the associations with REL, we carried out a replication study on 
independent sets of 2604 cases and 2882 controls from the U.S. and Canada (Supplementary 
Table 1B). While complete serologic data were not available for all subjects, the majority of 
cases were seropositive (either rheumatoid factor or CCP+) in the replication datasets. In 
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addition to selected SNPs from the REL locus, we also included candidate SNPs from the 
CTLA4 and BLK regions. For technical reasons, slightly different SNP panels were utilized 
for the replication studies in the Canadian and U.S. samples, based on tagging LD provided 
in the HapMap, and the results from the separate datasets are provided in Supplementary 
Table 2. The combined results with common SNPs markers across all the datasets are shown 
in Table 1 for REL, CTLA4 and BLK. Two highly associated SNPs at the REL locus are 
observed in the combined data using a Cochrane-Mantel-Haenszel analysis to allow for 
stratification among populations (rs13031237, OR=1.24, p = 3.08 × 10-14 and rs13017599, 
OR=1.21, p= 2.06 × 10-12). A graphical representation of the association results across the 
REL locus is shown in Figure 2. In addition, the data in Table 1 (and supplemental Table 2) 
provide definitive evidence for the previously suggested association with CTLA4 (rs 231735, 
OR=0.86, p=6.25 × 10-9). The data also support BLK as a new RA risk locus (rs2736340, 
OR 1.19, p=5.69 × 10-9), a finding of some interest given the recent association of this locus 
with systemic lupus11,12. Supplementary table 4 presents genotype-specific results, which 
show codominance for all the loci except CTLA4, which is nearly dominant.
The nuclear factor-κB (NF-κB)/REL family of transcription factors contain five members 
including c-Rel, p65/Rel-A, Rel-B, p50/NFkB-1 and p52/NFkB-2. These factors have a 
central role in coordinating the expression of a wide variety of genes that control immune 
responses and autoimmunity13. Therefore, the identification of REL, encoding c-Rel, as a 
new risk locus for RA has provoked us to consider how this observation may fit in with 
pathways suggested by the complex emerging landscape of genetic susceptibility for RA. 
While the various NF-κB subunits have complex overlapping functions, current data suggest 
some distinct roles for c-Rel. The production of IL12 and IL23 subunits by macrophages and 
dendritic cells are critically dependent on c-Rel14,15. Thus, c-Rel knockout animals exhibit 
deficiencies in Th1-type immune responses, although intrinsic T cell defects may also 
contribute to this phenotype16. Intriguingly, both c-Rel and another recently identified RA 
risk gene, PRKCQ, are specifically involved in the survival of activated CD8 cells, at least 
in part through the regulation of IL2 production by these cells. In addition, a variety of genes 
in T cells are regulated by c-Rel, including CD40 and TNFAIP3, both of which are now 
accepted RA susceptibility loci17.
In addition to effects on T cell and antigen presenting cell function, c-Rel has been shown to 
have a role in B cell proliferation and survival that particularly involves CD40 signaling 
pathways. Specifically, c-rel deficient B cells are susceptible to BCR induced apoptosis that 
cannot be prevented by activation through CD4018. This is due to reduced expression of the 
anti-apoptotic protein Bcl-XL, a gene that is known to be regulated by c-Rel. Interestingly, 
rescue from Fas induced apoptosis is normal in these cells, demonstrating the existence of 
distinct CD40 signaling pathways that are at least in part distinguished by the involvement 
of c-rel. A similar c-rel associated difference in CD40 signaling has been seen in patients 
with ectodermal dysplasia and hyperIgM syndrome due to mutations in the NF-κB essential 
modulator, NEMO, where c-Rel dependent IL4 responses are also impaired19. C-Rel is the 
only NF-kappaB family member with oncogenic activity and the gene is amplified in some 
B cell lymphomas. Intriguingly, in both tumors and normal B cells it has recently been 
reported that the CD40 and c-Rel proteins can physically interact and form a heterodimer 
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that is translocated to the nucleus20 and has transcriptional regulatory activity for known c-
rel target genes, including CD154, BLyS/BAFF, and Bfl-1/A1.
The associations of CD402, REL, TRAF18 and TNFAIP3 21are consistent with an important 
role for CD40 signaling pathways in RA pathogenesis. Indeed, CD40-CD40 ligand 
interactions have previously been identified as a potential target for therapy in autoimmune 
disease22, and clinical trials in lupus have shown promise23. Unfortunately, the clinical 
development of monoclonal antibody inhibitors of CD40L was cut short by adverse effects 
on the platelet function associated with the development of thromboembolic complications. 
Nevertheless, this pathway remains viable as a therapeutic target, and the current results 
mandate a thorough analysis of all the genes in this pathway to search for additional 
susceptibility alleles
METHODS
Subjects
The cases and controls utilized in this analysis were taken from a variety of collections in 
both the U.S. and Canada, as detailed below. The genome-wide association data from 868 
RA cases and 1194 controls from North America have been previously reported in a study of 
susceptibility loci for rheumatoid arthritis8; all the additional genome-wide association data 
(1550 cases and 3310 controls) and all the replication sample data (2604 cases and 2882 
controls) have not been previously reported in a RA association study. Informed consent 
was obtained from all subjects and these studies were approved by the Institutional Review 
Board of the North Shore LIJ Health System.
Subjects - U.S Cohorts
For our WGA analysis, we included WGA data on 868 North American RA cases samples 
reported previously8. We refer to these samples as “NARAC I”. All cases included in the 
current analysis are anti-CCP positive.
Details for patient collections used to compile the “NARAC II” dataset (N=952) used for 
final analysis on the Illumina HapMap370 chip are as follows.
1. RA probands in NARAC collection of affected sibling pair families in whom 
siblings did not meet criteria for RA (N=17), as well as probands of NARAC trio 
families (N=158). Collection criteria are previously published 8. No affected 
members of these families were included in our previously published GWAS 8. 
Only CCP+ patients were studied in the current analysis.
2. The Veterans Affairs Rheumatoid Arthritis Registry (VARA). VARA subjects, all 
meeting classification criteria for RA are currently being enrolled from six VA 
centers (Dallas, Denver, Jackson, Omaha, Salt Lake City, and Washington, DC). 
VARA is a longitudinal observational study that was started by Dr. Ted Mikuls at 
the University of Omaha. As of May 1, 2008, over 1,100 subjects have been 
enrolled. Of the 332 patients included in this analysis, 301 were documented to be 
CCP+ (N=332).
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3. The Studies of Etiologies of Rheumatoid Arthritis (SERA) cohort. This NIH-
funded (R01 AR051394) cohort study is co-directed by Drs. Michael Holers and 
Jill Norris at the University of Colorado Denver. SERA is a multi-center 
prospective cohort study designed to investigate genetic and epidemiologic 
associations with RA-related autoimmunity during the pre-clinical period of RA 
development. For the SERA study, probands with RA are recruited by 
Rheumatologists from clinics at the University of Colorado Denver School of 
Medicine (UCDSOM), Cedars-Sinai Medical Center, Los Angeles, California, the 
Rheumatoid Arthritis Investigation Network (RAIN) centered in Omaha, Nebraska, 
North Shore-Long Island Jewish Health System/Feinstein Institute for Medical 
Research, and the Benaroya Research Institute at Virginia Mason, Seattle, 
Washington. Additionally, probands are recruited through community outreach 
efforts and advertisements posted in the Arthritis Foundation Newsletter. Once a 
proband with RA has expressed interest in the study and consents for release of 
medical information, their medical charts are reviewed by a SERA Rheumatologist 
to ensure a diagnosis of RA. Probands are considered to have RA if they meet 4 of 
7 of the ACR 1987 Revised Classification Criteria for RA.(Arnett et al) or if they 
have been determined to have RA based on a clinical evaluation by a board-
certified Rheumatologist. Only CCP+ patients were studied in the current analysis 
(N=160).
4. Multiple Autoimmune Disease Genetics Consortium (MADGC). The MADGC 
collection of multiplex families includes RA patients enrolled who meet 1987 ACR 
criteria for disease. The details of the MADGC collection are previously 
published24. Only CCP+ patients were studied in the current analysis (N=105).
5. UCSF Rheumatoid Arthritis Genetics Project. Participants in the UCSF 
Rheumatoid Arthritis Genetics Project collection were recruited from UCSF 
Arthritis Clinics and private rheumatology practices in northern California as well 
as by nation wide outreach according to a protocol approved by the University of 
California, San Francisco Institutional Review Board. All patients fulfilled 1987 
ACR criteria for RA. All patients are of European origin based on self-report, 
including grandparental countries of origin. Only CCP+ patients were studied in the 
current analysis (N=86).
6. Early Rheumatoid Arthritis Treatment Evaluation Registry (ERATER). 452 
patients with RA of less than 3 years duration were enrolled in the ERATER study 
in Nashville, Tennessee between February 2001 and August 2004, including 336 
patients from a private practice of Arthritis Specialists of Nashville, 48 from 
Vanderbilt University Rheumatology Clinics, and 68 from other sites. A detailed 
decription of this cohort has been published 25. Only CCP+ patients were studied 
in the current analysis (N=94).
Controls for the replication WGA were taken from control datasets that are publicly 
available in the Ilumina iControl datasbase. (www.illumina.com/iControlDB, Illumina, San 
Diego, CA). Additional control genotypes were from the neurodevelopmental control group 
obtained from the NIH Laboratory of Neurogenetics (http://neurogenetics.nia.nih.gov/
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paperdata/public/). These control genotypes were selected from the entire set of European 
American genotypes available from these resources based on the following data filters: 1) > 
90% complete genotyping data; 2) HW > 10-4; and 3) >90% European continental ancestry. 
The European continental ancestry was determined using ancestry informative markers as 
previously described11. In addition we utilized control derived from a recent GWA study of 
lung cancer26 None of these controls overlap with controls utilized for the previously 
reported NARAC WGA study8. A third set of 1137 controls samples from M.D. Anderson 
Cancer Center Lung Cancer Study were used. These healthy individuals were seen for 
routine care at Kelsey-Seybold Clinics in the Houston Metropolitan area; all control subjects 
were required to have been current or former smokers.
The “NARAC II Replication” dataset contained RA patients from the following sources.
1. Treatment of Early Arthritis (TEAR) Trial. The TEAR trial is an investigator-
initiated multicenter trial comparing two different strategies (early intensive 
therapy versus step-up therapy) and two combinations of medications (etanercept 
plus methotrexate [MTX] versus MTX plus hydroxychloroquine [HCQ] plus 
sulfasalazine [SSZ]). Patients under study are those with early RA and an 
aggressive clinical phenotype defined by presence of active synovitis of multiple 
joints, with positive RF or baseline erosions as assessed by radiographs of hands or 
feet. 347 RF+ patients and 50 RF- patients were studied (N=397).
2. The National Data Bank for Rheumatic Diseases (NDBRD). The National 
Databank is a longitudinal cohort of RA patients which has been described 
previously27. There is no overlap between the samples used in the previous WGA 
and the samples used for replication reported here. Of the 312 patients included for 
study, 258 were documented to be anti-CCP+, 15 were anti-CCP-, and 39 subjects 
were not tested (Total N=312)
3. The National Inception Cohort of Rheumatoid Arthritis (NICRA). The NICRA 
enrolled patients within 6 months of clinical diagnosis and has been described in 
previous publications28. Only CCP+ patients were studied in the current analysis. . 
There is no overlap between the samples used in the previous WGA and the 
samples used for replication reported here. (N=52)
4. Study of New Onset Rheumatoid Arthritis (SONORA). The SONORA enrolled RA 
patients and patients with polyarthritis within 12 months after clinical diagnosis. 
29. Only patients meeting 1987 ACR critieria for RA and who were CCP+ were 
included in the current study. There is no overlap between the samples used in the 
previous WGA and the samples used for replication reported here. (N=184)
5. The GCI (Genomics Collaborative, Inc.) sample set consisted of 475 RA cases and 
475 individually-matched controls. All case samples met the 1987 American 
College of Rheumatology diagnostic criteria for RA. All case samples were white 
North Americans of European descent who were rheumatoid factor positive. 
Control samples were healthy white individuals with no medical history of RA, 
also of European descent. A single control was matched to each case on the basis of 
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sex, age (+/- 5years), and self-reported ethnic background. Informed written 
consent was obtained from every subject.
Note that for analytic purposes, the NDRBD, NICRA, and SONORA cohorts were 
combined into a case group designated “OPA3” as shown in Supplementary Table 1B and 
Table 2.
Control subjects for replication “NARAC II- replication studies were taken in part from the 
New York Cancer Project 30 collection using subjects with self reported European ancestry 
(N=1163). Random matching of these controls (Supplementary Table 1B) with the TEAR 
and OPA3 replication datasets simply reflects the logistics of how replication genotyping 
was batched and has been used as a convenient way of grouping the analysis, shown in 
Supplementary Table 2. Additional controls were taken from the Controls (N=474) for the 
GCI collection are described above.
Subjects - Canadian cohorts
1. Unrelated RA probands (N = 598)for the WGA study were recruited from the 
Toronto area, the diagnosis of RA based on clinical, serological and radiological 
data in accordance with 1987 American College of Rheumatology criteria for RA. 
Subjects diagnosed with RA at an age of 16 years or younger were excluded from 
the study. Control samples (N=413) were individuals of European origin from the 
Toronto area who had no history of rheumatoid arthritis or other inflammatory 
disease. Informed consent, demographic data and blood samples for genomic DNA 
extraction were obtained from every subject following Institutional ethics 
committee approval.
2. A second , independent set of RA patients and healthy controls of European origin 
for replication were recruited from the Toronto(601) and Halifax(564) areas based 
on the criteria described above. Controls for the replication study were recruited in 
Toronto (N=921) and Halifax (N=324) again based on the criteria described above.
Genotyping and Quality Control Filtering
The NARAC-II and Canadian case control collections were genotyped using 373,400 SNPs 
on the Illumina HapMap370 BeadChip. Genotyping of the NARAC-II dataset was carried 
out at the Feinstein Institute for Medical Research while the Canadian samples were 
genotyped at Illumina in San Diego, CA. In order to organize the data to permit integration 
of results among studies, all genotypes were called using BeadStudio Software according to 
Top designation (http://www.illumina.com/downloads/TOPBOT_technote27Jun06.pdf). 
Each data set was subjected to quality control filtering based on SNP genotype call rates 
(>95% completeness), minor allele frequency (>0.01), and the Hardy-Weinberg equilibrium 
(P>1×10-4). Subjects with more than 5% missing genotype data or showing evidence of 
non-European ancestry were excluded. In addition samples showing evidence of relatedness 
to another sample, or possible DNA contamination, were also excluded. After filtering, 
genotypes derived from SNP markers that were common to both datasets were merged into a 
single file for analysis. A summary of all samples utilized for analysis after data cleaning is 
given in Supplementary Table 1. These filters were applied to each data set independently 
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and SNPs that passed quality control filters in each data set were then merged. In all a total 
of 278502 SNPs passed all filters
Replication genotyping of selected markers of interest was carried out using Sequenom 
iPlex technology at the Analytic Genetics Technology Centre in Toronto (Canadian 
samples) or within the Genetics and Genomics Branch of the National Institutes of Arthritis 
and Musculoskeletal and Skin Diseases (NARAC II-Replication dataset). The GCI cohort 
was genotyped using a kinetic PCR assay at Celera Diagnostics. Slightly different panels of 
SNPs were selected for replication in each dataset, based on technical considerations for 
efficient multiplexing of markers. The patterns of linkage disequilibrium reported in the 
HapMap informed the selection of replacement markers to develop marker sets for the 
replication studies. For rs13031237 and rs2736340, the PCR reaction provided results on the 
alternate strand (T/G for A/C and T/C for A/G, respectively for rs13031237 and rs2736340).
To allow for potential effects of population substructure and heterogeneity among 
populations we employed several techniques. In initial analyses of genome-wide data, we 
combined marker genotypes of all individuals and performed analyses to identify clusters of 
individuals who had similar genotypes using the program PLINK, with the clustering 
criterion set at PPC set at 0.0001. We also applied the program Eigenstrat to perform 
association analysis adjusting for correlations among the subjects according to marker 
similarities. For both clustering analyses in PLINK and construction of Eigenvectors using 
Eigenstrat we first removed SNPs on chromosomes 6p near the HLA region, 8p, and 17p 
that contain large polymorphic inversions. We removed these SNPs as the HLA region 
contains many SNPs relating to case-control status and including them could reduce our 
power to detect true associations. On the other hand the SNPs in chromosomes 8p and 17p 
show different LD patterns compared with other SNPs throughout the genome and we 
removed these regions to avoid influencing the results due to the potential chance variations 
caused by effects from many markers in these regions that are not of interest for correcting 
for population structure but that may show stronger correlations among subjects than 
expected.
To check for gene-gene interactions we evaluated all possible interactions between SNPs in 
CTLA4, Rel, and BLK were performed for the 157 most significantly associated non-HLA 
region SNPs with rheumatoid arthritis. Results showed no interaction effects with 
significance levels below p< 0.001. Given that 471 tests were performed, no significant 
interaction effects were identified, after correcting for multiple testing.
Lambda values indicating population structure varied among the populations being studied 
and according to the test conducted. For NARAC, the lambda value after correcting to a 
sample of 1000 cases and 1000 controls using PLINK was 1.148 and for Eigenstrat lambda 
was 1.029. For the Canadian sample, lambdas were 0.996 for PLINK and 1.010 for 
Eigenstrat. For the combined sample, the lambda value was 1.077 for PLINK and 1.023 for 
Eigenstrat.
Gregersen et al. Page 9
Nat Genet. Author manuscript; available in PMC 2010 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Summary of genome-wide association scan results for 2418 cases and 4504 controls. The -
log10 of the trend test P values after homogeneous clustering and corrected for the residual 
genome wide inflation of chi square are plotted against position on each chromosome. 
Chromosomes are shown in alternating colors for clarity. The blue horizontal line indicates 
SNPs that are significant at a level (P = 5 × 10-5). The results for markers in the HLA region 
are truncated.
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Figure 2. 
Association localization plots in the region around REL following discovery and replication 
phases. The p values for all samples in the GWA scan are shown as small blue diamonds, 
with the exception of the results for two SNPs, rs13031237 and rs13017599 (P = 9.05 × 10-9 
and p = 6.01 × 10-10) in c-Rel , which are presented as red diamonds. The black diamonds 
show the independent results for these two SNPs in the replication samples.
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